Cargando…

Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif

This study aims to analyze the epidemiological, clinical, therapeutic and evolutionary profile of ocular manifestations in patients with Behçet’s disease. We conducted a retrospective, descriptive study of the medical records of 121 patients managed by specialists with expertise in this disease over...

Descripción completa

Detalles Bibliográficos
Autores principales: Razzak, Amine, Kassimi, Anass, Mchachi, Adil, Benhmidoune, Leila, Chakib, Abderrahim, Rachid, Rayad, Elbelhadji, Mohamed, Amraoui, Abdelouahed, Elkabli, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711680/
https://www.ncbi.nlm.nih.gov/pubmed/31489094
http://dx.doi.org/10.11604/pamj.2019.33.116.17111
_version_ 1783446550341484544
author Razzak, Amine
Kassimi, Anass
Mchachi, Adil
Benhmidoune, Leila
Chakib, Abderrahim
Rachid, Rayad
Elbelhadji, Mohamed
Amraoui, Abdelouahed
Elkabli, Hassan
author_facet Razzak, Amine
Kassimi, Anass
Mchachi, Adil
Benhmidoune, Leila
Chakib, Abderrahim
Rachid, Rayad
Elbelhadji, Mohamed
Amraoui, Abdelouahed
Elkabli, Hassan
author_sort Razzak, Amine
collection PubMed
description This study aims to analyze the epidemiological, clinical, therapeutic and evolutionary profile of ocular manifestations in patients with Behçet’s disease. We conducted a retrospective, descriptive study of the medical records of 121 patients managed by specialists with expertise in this disease over a period of one year and a half between January 2015 and June 2016. The average age of patients was 35 years, 63.6% of patients were male, ocular involvement was inaugural in 24% of cases. Patients had anterior uveitis (7.4%), posterior uveitis (15.7%), vasculitis (19%), irido-crystalline synechias (17.5%), macular edema (7.4%), optic atrophy (4.1%), papillary edema (2.5%) and peripheral retinal ischemia (1.7%). In our series, 41.3% of patients were under colchicine, 23.1% under oral corticosteroids, 9% under intravenous corticosteroids, 4.9% under topical corticosteroids, 8.2% under immunosuppressive drugs and 5.8% under vitamin K antagonists. After an average follow-up of 1 year, 40% of patients had stable visual acuity while receiving treatment, 23% had a significant decrease in visual acuity and 5% of cases had complete vision loss. Adequate therapy enables quick containment of the infection and decreases the frequency and severity of recurrences, thus leading to an improvement of the visual prognosis in our patients compared with outcomes in some previous case serie.
format Online
Article
Text
id pubmed-6711680
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-67116802019-09-05 Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif Razzak, Amine Kassimi, Anass Mchachi, Adil Benhmidoune, Leila Chakib, Abderrahim Rachid, Rayad Elbelhadji, Mohamed Amraoui, Abdelouahed Elkabli, Hassan Pan Afr Med J Case Series This study aims to analyze the epidemiological, clinical, therapeutic and evolutionary profile of ocular manifestations in patients with Behçet’s disease. We conducted a retrospective, descriptive study of the medical records of 121 patients managed by specialists with expertise in this disease over a period of one year and a half between January 2015 and June 2016. The average age of patients was 35 years, 63.6% of patients were male, ocular involvement was inaugural in 24% of cases. Patients had anterior uveitis (7.4%), posterior uveitis (15.7%), vasculitis (19%), irido-crystalline synechias (17.5%), macular edema (7.4%), optic atrophy (4.1%), papillary edema (2.5%) and peripheral retinal ischemia (1.7%). In our series, 41.3% of patients were under colchicine, 23.1% under oral corticosteroids, 9% under intravenous corticosteroids, 4.9% under topical corticosteroids, 8.2% under immunosuppressive drugs and 5.8% under vitamin K antagonists. After an average follow-up of 1 year, 40% of patients had stable visual acuity while receiving treatment, 23% had a significant decrease in visual acuity and 5% of cases had complete vision loss. Adequate therapy enables quick containment of the infection and decreases the frequency and severity of recurrences, thus leading to an improvement of the visual prognosis in our patients compared with outcomes in some previous case serie. The African Field Epidemiology Network 2019-06-14 /pmc/articles/PMC6711680/ /pubmed/31489094 http://dx.doi.org/10.11604/pamj.2019.33.116.17111 Text en © Amine Razzak et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Series
Razzak, Amine
Kassimi, Anass
Mchachi, Adil
Benhmidoune, Leila
Chakib, Abderrahim
Rachid, Rayad
Elbelhadji, Mohamed
Amraoui, Abdelouahed
Elkabli, Hassan
Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif
title Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif
title_full Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif
title_fullStr Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif
title_full_unstemmed Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif
title_short Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif
title_sort œil et maladie de behçet: profil épidémiologique, clinique, thérapeutique et évolutif
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711680/
https://www.ncbi.nlm.nih.gov/pubmed/31489094
http://dx.doi.org/10.11604/pamj.2019.33.116.17111
work_keys_str_mv AT razzakamine œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif
AT kassimianass œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif
AT mchachiadil œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif
AT benhmidouneleila œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif
AT chakibabderrahim œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif
AT rachidrayad œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif
AT elbelhadjimohamed œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif
AT amraouiabdelouahed œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif
AT elkablihassan œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif